Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.53 |
| ▸ | METAP2 | P50579 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.51 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.51 |
| ▸ | INSR | P06213 | 2/20 | 0.51 |
| ▸ | IGF1R | P08069 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29491224 | 1.00 | NOS1 (0.53) | NOS1MAPTDYRK1AMETAP2KDM4E | |
| SCHEMBL31243384 | 0.85 | NOS1 (0.50) | NOS1MAPTDYRK1AMETAP2KDM4E | |
| SCHEMBL1362997 | 0.85 | MAPK1 (0.55) | NOS1MAPTDYRK1AMETAP2KDM4E | |
| SCHEMBL30440513 | 0.85 | MAPK1 (0.55) | NOS1MAPTDYRK1AMETAP2KDM4E | |
| SCHEMBL8669605 | 0.84 | NOS1 (0.57) | NOS1MAPTDYRK1AMETAP2KDM4E | |
| SCHEMBL7132606 | 0.81 | NOS1 (0.58) | NOS1MAPTDYRK1AMETAP2KDM4E | |
| SCHEMBL20721589 | 0.81 | MAPT (0.53) | NOS1MAPTDYRK1AMETAP2KDM4E | |
| SCHEMBL30896276 | 0.81 | NOS1 (0.58) | NOS1MAPTDYRK1AMETAP2KDM4E | |
| SCHEMBL91332 | 0.81 | MAPT (0.60) | NOS1MAPTDYRK1AMETAP2KDM4E | |
| SCHEMBL10130202 | 0.81 | MAPT (0.58) | NOS1MAPTDYRK1AMETAP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12275727-B2 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | 280 BIO, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| EP-4488275-A1 | COMPOUND CONTAINING FIVE-MEMBERED HETEROAROMATIC RING STRUCTURE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Yingli Pharmaceutical Co., Ltd (CN) | 2025-01-08 | — | — | EP | disclosed |
| CN-115515956-B | Benzimidazole derivative, and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-110506038-B | Pesticidal compounds | 巴斯夫欧洲公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230278998-A1 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | 280 BIO, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| WO-2023165571-A1 | COMPOUND CONTAINING FIVE-MEMBERED HETEROAROMATIC RING STRUCTURE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海璎黎药业有限公司 | 2023-09-07 | — | — | WO | disclosed |
| US-20230278998-A1 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | 280 BIO, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230278998-A1 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | 280 BIO, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| CN-116693519-A | Compound containing five-membered heteroaromatic ring structure, pharmaceutical composition and application thereof | 上海璎黎药业有限公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-3601231-B1 | PESTICIDAL COMPOUNDS | BASF SE (DE) | 2023-05-10 | — | — | EP | disclosed |
| WO-2009054983-A1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| EP-1385833-A1 | TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | Amgen Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002083654-A1 | TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AMGEN INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275727-B2 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | PARG, CYP3A5, CYP11B1 | NOS1 2450/4885MAPT 1695/4885DYRK1A 3747/4885 |
| US-20080176896-A1 | Modulators of cellular adhesion | ITGB1, VCAM1, ITGB8 | NOS1 1989/4885MAPT 3828/4885DYRK1A 4212/4885 |
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | S1PR1, S1PR2, S1PR4 | NOS1 1462/4885MAPT 3251/4885DYRK1A 2216/4885 |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | NOS1 1988/4885MAPT 3830/4885DYRK1A 4210/4885 |
| US-20230278998-A1 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | PARG, CYP3A5, CYP11B1 | NOS1 2450/4885MAPT 1695/4885DYRK1A 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.